

# What Does REVEAL Reveal?

## MDMcGoonMD on behalf of REVEAL Investigators

### Planning and Articulation of Objectives

1. Characterize demographics/course of WHO Group I
2. Outcomes of WHO Group I subgroups
3. Outcomes according to hemodynamic criteria
4. Identify clinical predictors of outcomes
5. Effect of treatment strategies on outcomes
6. Describe diagnostic and management patterns
7. Generate hypotheses

### Goals and Accomplishments

- Complete enrollment of 3,000 patients in the REVEAL Registry by end of 2007 calendar year
  - August 07: 3,000 patients enrolled
- Total of at least 50 sites enrolling patients
  - Total of 55 enrolling sites
  - All activated sites enrolled patients
  - 6 pediatric sites
- Minimum of two abstracts and two main publications
  - 4 Abstracts: 3 Chest and 1 ISHLT
  - 2 Main publications
    - design manuscript
    - baseline demographics manuscript


### REVEAL Registry Status Update

- Current Enrollment
  - 3,088 patients enrolled at 55 sites (as of 10/29/07)
    - 92% completion of the Enrollment CRFs
  - 3,060 patients enrolled in initial cohort (newly and previously diagnosed)
- Amendment #2: Expansion to include 500 newly diagnosed patients
  - Approximately 800-900 newly diagnosed patients
- Monitoring Activities (target 20% of sites annually)
  - 10 Monitored sites to date:
    - LDS Hospital, Colorado, Pennsylvania, Denver Children's Hospital, Pittsburgh, Duke, and Johns Hopkins, UCLA, UCSF, Mayo Rochester


### Top 15 Enrolling Sites as of 9.24.07

Site	Total Patients Enrolled
Mayo Clinic, Rochester	211
University of Colorado HSC	197
University of Pennsylvania Med Center	162
Baylor College of Medicine	151
Duke University	150
UCLA West Los Angeles VA	135
Cleveland Clinic Foundation	107
Johns Hopkins Medical Center	103
UCSF Medical Center	92
UCSD Medical Center	87
Columbia University Medical Center	82
LDS Hospital	75
University of Pittsburgh Medical center	74
Denver Children's Hospital	71
University of Rochester Medical Center	68
Vanderbilt University Medical Center	59

### Percent of Patients on PAH Specific Therapies at Enrollment (Excludes Blinded Trial Patients)



### Monotherapy Use By Functional Class at Enrollment (Excludes Blinded Trial Patients)



### Patients on Therapy At Time of Enrollment

# of PAH Medications	N	Percentage
0	87	6
1	658	45
2	567	39
3	136	9
4	7	<1
5	1	<1

N = 1,456 (Excludes blinded trial patients)  
1,369 (94%) on any PAH specific medication

711 (52%) of 1,369 patients on therapy are on more than one PAH medication

### Combination of Any Oral Therapy and Any Prostaglycin NYHA Class III and IV at Enrollment (Excludes Blinded Trial Patients)

